In a report issued on March 1, Jason Butler from JMP Securities reiterated a Buy rating on Esperion (ESPR), with a price target of $153. The company’s shares closed yesterday at $47.06.
According to TipRanks.com, Butler is a 5-star analyst with an average return of 15.7% and a 50.9% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aevi Genomic Medicine Inc, Axovant Gene Therapies, and Myovant Sciences.
Currently, the analyst consensus on Esperion is a Moderate Buy with an average price target of $93.80, representing a 99.3% upside. In a report issued on March 1, Northland Securities also maintained a Buy rating on the stock with a $65 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $81.29 and a one-year low of $33.06. Currently, Esperion has an average volume of 574.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
